NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









ImaginAb

ImaginAb

Private
Inglewood, CaliforniaHealthcare & Life Scienceshttps://imaginab.com/

Last Round

Series C

Extension

Sep 14, 2023

Total Funding Raised

$57.8M

Company Overview

ImaginAb is a biotechnology company that develops radiopharmaceutical imaging agents and therapies, including its proprietary CD8 ImmunoPET technology for cancer immunotherapy monitoring.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Imaging, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Non-AI

Keywords

minibodyimmunoPETmolecular imagingantibody fragmentCD8 PET imagingradiopharmaceuticaldiagnostic imagingimmunotherapy monitoringclinical trial imagingPET tracerprecision medicinebiotech licensingin vivo imagingtheranostics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ImaginAb Comparables

Compare ImaginAb with similar companies based on industry and business-model similarity.

ImaginAb comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
CellSight Technologies
86%
Suzhou SmartNuclide Biopharmaceutical Co., Ltd.
76%
Bracco S.p.A.
74%

ImaginAb Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series C ExtensionSep 14, 2023
Series C ExtensionMar 14, 2023
Series CJun 3, 2021
Series B ExtensionOct 9, 2017
Series BMay 8, 2014
Series A
Mar 26, 2012

Key People

Founding team and executive leadership

David Fractor

CFO

Executive Team

ImaginAb Investors

Notable investors and investment history

ImaginAb investors
InvestorRounds
National Cancer InstituteGrant
Norgine VenturesSeries C
Momentum BiosciencesSeries A
Parker Institute for Cancer ImmunotherapySeries B Extension
InnovivaSeries C Extension
Cycad GroupSeries A, Series B Extension, Series B, Series C
The Raptor GroupSeries B Extension, Series C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 9, 2017

    $8M round led by Adage Capital Management.

  • May 8, 2014

    $21M round led by Mérieux Equity Partners.

ImaginAb Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

ImaginAb Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about ImaginAb's valuation, stock price, and market status.

Firmographic Details

HeadquartersInglewood, California
Employee Range12
Year Founded2007
Last FundingSep 14, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.